MELBOURNE, Australia, Jan. 30 /PRNewswire-FirstCall/ -- Phosphagenics Limited ("Phosphagenics") (ASX: POH, AIM: PSG, OTCQX: PPGNY) today announced results of a pre-clinical study demonstrating that the combination of its APA- 01 product candidate and the statin atorvastatin (Lipitor(TM)) significantly reduced serum lipids and inflammatory proteins involved in the development of atherosclerosis.
The purpose of the study was to determine whether a combination of the statin drug atorvastatin and APA-01 could reduce serum lipids, inhibit atherosclerotic lesion progression and reduce proinflammatory cytokines and other biomarkers of inflammatory disease more effectively than the statin alone.
Studies were performed in ApoE mice, animals that spontaneously form atherosclerotic plaques and represent a well-established model of human atherogenic hyperchosterolemia.
During the first 16-weeks of this 24-week study, all animals in the experimental group were maintained on a standard diet, followed by an eight week treatment period in which this diet was supplemented with 21% fat and 0.15% cholesterol, an atherogenic diet expected to accelerate atherosclerotic progression. All animals in the experimental groups received drug treatment in both their normal and high-fat diets at various dosing regiments throughout the 24-week study. Control group animals received no drug treatment and were maintained on either the same diet as the treatment groups or on a standard diet.
Effects on Serum Lipids
The study results indicated that among the animals treated with the
APA-01 and atorvastatin combination, total cholesterol levels fell by up to
an additional 12% compared to those animals treated with atorvastatin
alone. Total HDL-C (good cholesterol) levels increased by up to 37% in
combination drug-treated animals, while LDL-C (bad cholesterol) levels were
further reduced by up to 24% with the combination,
|SOURCE Phosphagenics Limited|
Copyright©2008 PR Newswire.
All rights reserved